Fatty liver is a sensitive early warning for hypertension and its complication in the Chinese population.

IF 1.5 4区医学 Q3 PERIPHERAL VASCULAR DISEASE Clinical and Experimental Hypertension Pub Date : 2022-05-19 DOI:10.1080/10641963.2022.2029469

Xin-Ping Zhu, Gao-Chao Han, Qiang Chen, Zheng-Yan Zhang, Li-Shun Wang, Bo Zhang

{"title":"Fatty liver is a sensitive early warning for hypertension and its complication in the Chinese population.","authors":"Xin-Ping Zhu, Gao-Chao Han, Qiang Chen, Zheng-Yan Zhang, Li-Shun Wang, Bo Zhang","doi":"10.1080/10641963.2022.2029469","DOIUrl":null,"url":null,"abstract":"Objective: The patient of hypertension and its complication increase fast in the past years. Obesity is thought to be a risk factor for hypertension, and BMI (body mass index) is widely used to evaluate the obesity and hypertension risk. However, the abdominal obesity and visceral fat accumulation are more obvious in the East Asian population. The aim of this study was to evaluate the predictive value of fatty liver for hypertension in the Chinese population.Method: We compared the predictive value of BMI and fatty liver for the hypertension and its complication in 1386 patients with hypertension in Shanghai China.Results: In the analysis of 1386 patients with hypertension in Shanghai China, we found that the prevalence and risk of hypertension and its complications were higher in the fatty liver group than that in the group of BMI≥24. Furthermore, the areas under the ROC curve of fatty liver for hypertension and its complications were superior to that of BMI.Conclusion: These results suggested that fatty liver is a more sensitive early warning for hypertension and its complication than BMI in Chinese population.","PeriodicalId":10333,"journal":{"name":"Clinical and Experimental Hypertension","volume":"44 4","pages":"306-312"},"PeriodicalIF":1.5000,"publicationDate":"2022-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10641963.2022.2029469","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 1

Abstract

Objective: The patient of hypertension and its complication increase fast in the past years. Obesity is thought to be a risk factor for hypertension, and BMI (body mass index) is widely used to evaluate the obesity and hypertension risk. However, the abdominal obesity and visceral fat accumulation are more obvious in the East Asian population. The aim of this study was to evaluate the predictive value of fatty liver for hypertension in the Chinese population.

Method: We compared the predictive value of BMI and fatty liver for the hypertension and its complication in 1386 patients with hypertension in Shanghai China.

Results: In the analysis of 1386 patients with hypertension in Shanghai China, we found that the prevalence and risk of hypertension and its complications were higher in the fatty liver group than that in the group of BMI≥24. Furthermore, the areas under the ROC curve of fatty liver for hypertension and its complications were superior to that of BMI.

Conclusion: These results suggested that fatty liver is a more sensitive early warning for hypertension and its complication than BMI in Chinese population.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

脂肪肝是中国人群高血压及其并发症的敏感预警。

目的:近年来高血压患者及其并发症快速增加。肥胖被认为是高血压的危险因素，BMI(身体质量指数)被广泛用于评估肥胖和高血压的风险。而腹部肥胖和内脏脂肪堆积在东亚人群中更为明显。本研究的目的是评估脂肪肝对中国人群高血压的预测价值。方法:比较BMI和脂肪肝对上海市1386例高血压患者高血压及其并发症的预测价值。结果:在对中国上海地区1386例高血压患者的分析中，我们发现脂肪肝组高血压及其并发症的患病率和风险高于BMI≥24组。此外，脂肪肝对高血压及其并发症的ROC曲线下面积优于BMI。结论:在中国人群中，脂肪肝是比BMI更敏感的高血压及其并发症的预警指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical and Experimental Hypertension 医学-外周血管病

CiteScore

3.90

自引率

0.80%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical and Experimental Hypertension is a reputable journal that has converted to a full Open Access format starting from Volume 45 in 2023. While previous volumes are still accessible through a Pay to Read model, the journal now provides free and open access to its content. It serves as an international platform for the exchange of up-to-date scientific and clinical information concerning both human and animal hypertension. The journal publishes a wide range of articles, including full research papers, solicited and unsolicited reviews, and commentaries. Through these publications, the journal aims to enhance current understanding and support the timely detection, management, control, and prevention of hypertension-related conditions. One notable aspect of Clinical and Experimental Hypertension is its coverage of special issues that focus on the proceedings of symposia dedicated to hypertension research. This feature allows researchers and clinicians to delve deeper into the latest advancements in this field. The journal is abstracted and indexed in several renowned databases, including Pharmacoeconomics and Outcomes News (Online), Reactions Weekly (Online), CABI, EBSCOhost, Elsevier BV, International Atomic Energy Agency, and the National Library of Medicine, among others. These affiliations ensure that the journal's content receives broad visibility and facilitates its discoverability by professionals and researchers in related disciplines.